TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00714246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Dose escalation using traditional Phase I - 3 x 3 design to establish MTD of bortezomib when administered in combination with carboplatin and docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Dose escalation using traditional Phase I - 3 x 3 design to establish MTD of bortezomib when administered in combination with carboplatin and docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Dose escalation using traditional Phase I - 3 x 3 design to establish MTD of bortezomib when administered in combination with carboplatin and docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Dose escalation using traditional Phase I - 3 x 3 design to establish MTD of bortezomib when administered in combination with carboplatin and docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Dose escalation using traditional Phase I - 3 x 3 design to establish MTD of bortezomib when administered in combination with carboplatin and docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Dose escalation using traditional Phase I - 3 x 3 design to establish MTD of bortezomib when administered in combination with carboplatin and docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Dose escalation using traditional Phase I - 3 x 3 design to establish MTD of bortezomib when administered in combination with carboplatin and docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Establish MTD of bortezomib when administered in combination with carboplatin and docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Establish MTD of bortezomib when administered in combination with carboplatin and docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Establish MTD of bortezomib when administered in combination with carboplatin and docetaxel
Study: NCT02684370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo for ustekinumab
Description: Placebo for ustekinumab administered by subcutaneous (SC) injection
Study: NCT00627094

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biatain
Description: A standard polyurethane foam dressing Biatain non-adhesive (Coloplast A/S) with an elastic semi-permeable backing film, size 15x15 cm. The product is CE marked.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biatain Ibu
Description: Biatain Ibu non-adhesive (Coloplast A/S), a polyurethane foam dressing with an elastic semi-permeable backing film with an added pain relieving medicinal substance ibuprofen (Albermarle Inc.), size 15x15 cm. The product is CE marked.
Study: NCT01650142

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT01861431

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HIV Sexual Risk reduction
Description: 4 sessions of HIV sexual risk reduction

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV Sexual Risk reduction plus Microfinance
Description: 4 sessions of sexual risk reduction plus 12 sessions of financial literacy, 12 sessions of business development training, 10 sessions of business mentorship; matched savings throughout course of intervention
Study: NCT04238494

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Nuclear magnetic resonance (NMR)
Description: Muscle architecture, lipid and active tissue muscle content should be measured. Proton NMR imaging (MRI)

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Nuclear magnetic resonance (NMR)
Description: Muscle architecture, lipid and active tissue muscle content should be measured. Proton NMR imaging (MRI)
Study: NCT01232075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended letrozole regimen
Description: Letrozole (Femara; Novartis pharma AG, Basle, Switzerland) 2.5mg /day is administered from cycle day 1 to 9 .~Human chorionic gonadotropin (Pregnyl; N.V. Organon, Oss, Holland) ( 10.000 IU/I.M ) is administered to trigger ovulation when at least one follicle measures more than 18mm in mean diameter .Intrauterine insemination is performed 36 - 40 hours after HCG injection .~Starting from cycle day 9 , ultrasound scans are repeated daily to monitor follicle growth . Serum estradiol and endometrial thickness are measured on the day of HCG administration.~Serum B-subunit HCG is measured 2 weeks after IUI to diagnose pregnancy .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene citrate regimen
Description: Clomiphene citrate(Clomid; Aventis pharma S.AE, Global Napi pharmaceuticals, Cairo, Egypt) 100 mg/day is administered from cycle day 3 to 7.~Human chorionic gonadotropin (Pregnyl; N.V. Organon, Oss, Holland) ( 10.000 IU/I.M ) is administered to trigger ovulation when at least one follicle measures more than 18mm in mean diameter .Intrauterine insemination is performed 36 - 40 hours after HCG injection .~Starting from cycle day 9 , ultrasound scans are repeated daily to monitor follicle growth . Serum estradiol and endometrial thickness are measured on the day of HCG administration.~Serum B-subunit HCG is measured 2 weeks after IUI to diagnose pregnancy .
Study: NCT00399204

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone vs Metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone vs Metformin
Study: NCT00308555

Intervention type: DRUG
Group type: OTHER
Intervention: Cannabis
Study: NCT03157934

Intervention type: OTHER
Intervention: not applicable (observational study)
Description: Observational study without study related intervention

Intervention type: OTHER
Intervention: not applicable (observational study)
Description: Observational study without study related intervention

Intervention type: OTHER
Intervention: not applicable (observational study)
Description: Observational study without study related intervention
Study: NCT00380861

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total knee replacement using the PFC Sigma RPF knee implant.
Description: Total knee replacement

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total knee replacement using the PFC Sigma RP knee implant
Description: Total knee replacement
Study: NCT00641810

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caffeine reduction
Description: Reduction in daily caffeine consumption from usual amounts to none.
Study: NCT01269671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin, Peppermint Oil (mentharil), and Simethicone
Description: Dosing will be dependent on patient's age during time of enrollment. Patients 8-12 years of age will receive Melatonin 3mg tab at night, Peppermint oil 1 capsule (0.2ml) 30-60 minutes prior to meal twice daily, and Simethicone 80mg tab 30-60 minutes prior to meal twice daily. Patients 13-18 years of age will receive Melatonin 3mg tab at night, Peppermint oil 2 capsules (0.4ml) 30-60 minutes prior to meal twice daily, and Simethicone tab 125mg 30-60 minutes prior to meal twice daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: Patients in the placebo group will receive one placebo tab to be taken at night, one placebo capsule to be taken 30-60 minutes prior to meal twice daily, and one placebo tab to be taken 30-60 minutes prior to meal twice daily.
Study: NCT00968539

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK investigational vaccine GSK2340272A
Description: Two intramuscular injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK investigational vaccine GSK2340269A
Description: Two intramuscular injections
Study: NCT01469845

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 3% hypertonic saline
Description: 4 ml dose to be administered every 6 hours

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 3% hypertonic saline
Description: 4 ml dose to be administered every 6 hours
Study: NCT03464110

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communication Intervention
Description: . The intervention will contain elements of Motivational Interviewing coaching but also will teach providers how to address patient emotion and increase the efficiency of their visits. Clinicians randomized to the intervention will receive a tailored communication coaching intervention that includes didactic elements, audio recording encounters and providing feedback, and role-playing.
Study: NCT00714246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Establish MTD of bortezomib when administered in combination with carboplatin and docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Establish MTD of bortezomib when administered in combination with carboplatin and docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Establish MTD of bortezomib when administered in combination with carboplatin and docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Establish MTD of bortezomib when administered in combination with carboplatin and docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Establish MTD of bortezomib when administered in combination with carboplatin and docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Establish MTD of bortezomib when administered in combination with carboplatin and docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Establish MTD of bortezomib when administered in combination with carboplatin and docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Establish MTD of bortezomib when administered in combination with carboplatin and docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Establish MTD of bortezomib when administered in combination with carboplatin and docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Establish MTD of bortezomib when administered in combination with carboplatin and docetaxel
Study: NCT03192917

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low intensity extracorporeal shock wave treatment (LI-ESWT)
Description: Shock wave treatment with 3000 Hz for 10 min on the penile shaft. This will be done one time a week for five weeks.
Study: NCT00714246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Establish MTD of bortezomib when administered in combination with carboplatin and docetaxel
Study: NCT00833924

Intervention type: DEVICE
Group type: OTHER
Intervention: Zenith(R) Low Profile AAA Endovascular Graft
Description: The Zenith(R) Low Profile AAA Endovascular Graft and ancillary components are indicated for the endovascular treatment of patients with abdominal aortic, aorto-iliac, or iliac aneurysms having morphology suitable for endovascular repair.
Study: NCT01495481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine 2 mcg/kg, Intravenous push

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adenosine
Description: Stepwise incremental approach of adenosine starting at 0.2 mg/kg (max 6 mg) followed by 0.3 mg/kg (max 12 mg) if initial dose was unsuccessful
Study: NCT02126969

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low dose fractionated radiation - 80cGy with chemotherapy
Description: Chemotherapy + 80 cGy of RT

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel and Carboplatin AUC 6
Description: Docetaxel 75 mg/m2 and Carboplatin AUC 6 without Radiation
Study: NCT03192917

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Low intensity extracorporeal shock wave treatment (LI-ESWT) sham
Description: A specialized cap can be applied to the chock wave device, which disallow shock waves to transmit through the unit.
Study: NCT02181673

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive intravenous infusions of placebo at Weeks 0, 4, 12 and 20 in treatment Group 1 and intravenous infusions of placebo at Week 24 to maintain the blind in treatment Group 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive intravenous infusions of placebo at Weeks 0, 4, 12 and 20 in treatment Group 1 and intravenous infusions of placebo at Week 24 to maintain the blind in treatment Group 2.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Golimumab
Description: Participants will receive intravenous infusions of golimumab 2mg/kg at Weeks 0, 4 and thereafter every 8 weeks up to Week 52 in treatment Group 2 and intravenous infusions of golimumab (2mg/kg) at Weeks 24, 28 and thereafter every 8 weeks up to Week 52 in treatment Group 1.
Study: NCT01485861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: Orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: Orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Abiraterone
Description: Orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: Orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: Orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: Orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apitolisib
Description: Orally once daily
Study: NCT02181673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab
Description: Participants will receive intravenous infusions of golimumab 2mg/kg at Weeks 0, 4 and thereafter every 8 weeks up to Week 52 in treatment Group 2 and intravenous infusions of golimumab (2mg/kg) at Weeks 24, 28 and thereafter every 8 weeks up to Week 52 in treatment Group 1.
Study: NCT03176953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topiramate
Description: active medication
Study: NCT01485861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib
Description: Orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib
Description: Orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib
Description: Orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib
Description: Orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Orally bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Orally bid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Description: Orally bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Orally bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Orally bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Orally bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Orally bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Orally bid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisolone
Description: Orally bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Orally bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Orally bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Orally bid
Study: NCT02468466

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-level suicide prevention programs
Description: The intervention included both screening and educational components. The screening component invited residents aged 36-64 years to participate in a two-step screening program. In the initial screening, a self-report questionnaire were mailed to all of those residents in the priority districts with a past high suicide rate. The second stage was conducted for the participants who screened positive though a semi-structural interview. Based on the results, participants who were diagnosed with a major depressive episode were provided with a referral to a psychiatry and support for treatment adherence. Written feedback on the screening results was mailed to all respondents. The educational component was implemented through workshops open to the general public (3 times every year) and local public newsletters (twice every year) designed to improve access and adherence to treatment and to reduce stigma associated with suicide and depression.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Suicide prevention program as usual
Description: Usual mental health program (not including depression screening among middle-aged)
Study: NCT01427205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Loading dose 400 mg/m2 by vein once followed by 250 mg/m2 weekly (+/- 7 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Loading dose 400 mg/m2 by vein once followed by 250 mg/m2 weekly (+/- 7 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSI-906
Description: 150 mg by mouth twice a day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo taken by mouth twice daily.
Study: NCT02953834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: kisspeptin 112-121
Description: Dose: 0.313-12.5 mcg/kg Duration: up to 16 hours

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Insulin Resistance Test
Description: Eat or drink a standard meal OR drink a standard drink containing 75 grams of sugar

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Insulin Resistance Test
Description: Eat or drink a standard meal OR drink a standard drink containing 75 grams of sugar

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Receive IV fluids for up to 16 hours that do not contain any study drug
Study: NCT02561507

Intervention type: BEHAVIORAL
Intervention: Survey
Study: NCT02554110

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stimulator active device
Description: This is a stimulator active device that delivers peripheral nerve stimulation in conjunction with pulse oximetry information.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Stimulator sham Device
Description: This is an stimulator sham device that is not providing peripheral nerve stimulation.
Study: NCT02592473

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Embozene Microspheres
Description: Minimally invasive intra-arterial administration of particle embolics into prostate arteries under fluoroscopy and cone-beam CT imaging guidance.
Study: NCT00128180

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Intravenous methylprednisolone 16 mg/kg/day for 3 days as follows: 8 mg/kg (up to 500 mg) given over first hour followed by 8 mg/kg over the next 23 hours; then 16 mg/kg (up to 1000 mg) on days 2 and 3 administered over 24 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02028299

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 2D doppler echo with Definity solution
Description: Correlate right heart catheterization results with results from 2D doppler echo with Definity Solution
Study: NCT02093546

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood and tumor
Study: NCT03417661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEXI-PREP By Clinell Wipes
Description: Sterile single sachet wipe containing 3ml solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEXI-PREP By Clinell Wipes
Description: Sterile single sachet wipe containing 3ml solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloraprep
Description: Sterile applicator containing 3ml solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloraprep
Description: Sterile applicator containing 3ml solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: Sterile saline (0.9% w/v) wipe, containing 3ml of solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: Sterile saline (0.9% w/v) wipe, containing 3ml of solution.
Study: NCT05796128

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nasal Intermittent Positive Pressure Ventilation (NIPPV)
Description: In this group, infants will receive NIPPV during LISA procedure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal continuous positive airway pressure (NCPAP)
Description: In this group, infants will receive NCPAP during LISA procedure.
Study: NCT01173562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mebendazole
Description: Type= exact number, unit= mg, number= 500, form= chewable tablet, route= oral use. One mebendazole 500-mg chewable tablet taken on Day 1.
Study: NCT01854021

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intravenous anesthesia
Description: intravenous anesthesia

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: combined intravenous-inhalational anesthesia
Description: combined intravenous-inhalational anesthesia

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: inhalational anesthesia
Description: inhalational anesthesia
Study: NCT03363230

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness skills training
Description: Mindfulness skills were taught over a 10-week period. Mindfulness skills were delivered in a weekly group-format. Participants were instructed to follow mindfulness practice at home. The treatment was focused on enhancing the patient capacity to defuse from cognitive and emotional content.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interpersonal Effectiveness skills training
Description: Interpersonal effectiveness skills were taught over a 10-week period. Skills were delivered in a weekly group-format. The treatment was focused on improving interpersonal effectiveness.
Study: NCT02047110

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo for risankizumab
Description: Placebo for risankizumab administered by subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risankizumab
Description: Risankizumab administered by subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risankizumab
Description: Risankizumab administered by subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risankizumab
Description: Risankizumab administered by subcutaneous (SC) injection